C

2020 ASCO Update on Selinexor in R/R Multiple Myeloma: Does a Weekly 100 mg Dosing + Daratumumab/Dexamethasone Produce Deep and Durable Response?

By Cristina Gasparetto 3 Videos
June 25, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Memorial Sloan Kettering Cancer Center

MSKCC's Molecular Diagnostics in Clinical Practice

Fri, Nov 6, 2020
The Asian Oncology Society 1st Virtual International Conference

The Asian Oncology Society 1st Virtual International Conference

Fri, Nov 27, 2020
Total Health Conferencing

A Virtual Year in Review: How COVID-19 Transformed Clinical Care

Sat, Nov 7, 2020
19:57
Moffitt Cancer Center

Efficacy Analysis of Anti-CD38 in R/R Multiple Myeloma: What Is the Bene...

Feat. K. Shain
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the ...

Feat. J. Berdeja
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/...

12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refra...

Feat. M. Dimopoulos
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, ...

Feat. S. Jagannath
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial
25:01
Nebraska Oncology Society

2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer Surv...

Feat. A. Cohen
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko
08:25
Cristina Gasparetto

2020 ASCO Update on Selinexor in R/R Multiple Myeloma: What Is the Effec...

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Ac...

Feat. T. Martin
19:43
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Myeloma: KRd vs. VRd for Initial Therapy of Newly Di...

Feat. R. Vij
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
09:02
Maria-Victoria Mateos

FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma